-
公开(公告)号：US06667306B1
公开(公告)日：2003-12-23
申请号：US09226103
申请日：1999-01-07
申请人： Alan M. Laibelman , Hans-Michael Jantzen , Pamela B. Conley , Larry J. Fretto , Robert M. Scarborough
发明人： Alan M. Laibelman , Hans-Michael Jantzen , Pamela B. Conley , Larry J. Fretto , Robert M. Scarborough
IPC分类号： C07D51314
CPC分类号： C07D513/04
摘要： The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors: In formula (I), W is carbon or nitrogen, wherein at least one W is a carbon; and Y is nitrogen, oxygen, or sulfur. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.
摘要翻译： 本发明涉及含有作为有效血小板ADP受体抑制剂的稠合杂环体系的式（I）化合物：式（I）中W是碳或氮，其中至少一个W是碳; Y是氮，氧或硫。 包括药学上可接受的盐的这些化合物可用于预防和/或治疗心血管疾病，特别是血栓形成相关的各种药物组合物。
-
2.发明授权Methods of screening for compounds that interact with human P.sub.2u2 purinergic receptor 失效筛选与人类P2u2嘌呤能受体相互作用的化合物的方法
公开(公告)号：US6063582A
公开(公告)日：2000-05-16
申请号：US749707
申请日：1996-11-15
IPC分类号： C12N15/09 , A61K38/00 , A61K48/00 , C07K14/705 , C12N15/12 , C12Q1/68 , G01N33/50 , G01N33/566 , C12Q1/00
CPC分类号： G01N33/5091 , C07K14/705 , G01N33/5008 , G01N33/502 , G01N33/5041 , G01N33/5044 , G01N33/5094 , G01N33/566 , A61K38/00 , A61K48/00 , G01N2500/10
摘要： A novel subtype of the P.sub.2 -purinergic receptor, referred to as the P.sub.2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor and associated screening and therapeutic methods also are disclosed.
摘要翻译： 公开了称为P2U2受体的P2-嘌呤能受体的新亚型。 该受体由其四种激动剂按以下特异性顺序激活：UTP> UDP> ADP> ATP。 还公开了编码受体的核酸和相关筛选和治疗方法。
-
公开(公告)号：US06762029B2
公开(公告)日：2004-07-13
申请号：US09745842
申请日：2000-12-26
申请人： Pamela B. Conley , Hans-Michael Jantzen , Vanitha Ramakrishnan-DuBridge , David Jay Julius , Gunther Hollopeter
发明人： Pamela B. Conley , Hans-Michael Jantzen , Vanitha Ramakrishnan-DuBridge , David Jay Julius , Gunther Hollopeter
IPC分类号： G01N3353
CPC分类号： G01N33/5008 , A61K38/00 , C07K14/705 , C07K16/28 , G01N33/502 , G01N33/5091 , G01N33/74 , G01N2333/726 , G01N2500/02
摘要： The present invention includes a novel subtype of the P2-purinergic receptor, referred to as the P2Y12 receptor. This receptor is expressed selectively in the platelets and brain, and couples to a pertussis toxin-sensitive G protein (Gi). Nucleic acids encoding the receptor and associated screening and therapeutic methods are also disclosed.
摘要翻译： 本发明包括称为P2Y12受体的P2-嘌呤能受体的新亚型。 该受体在血小板和脑中有选择性表达，并且与百日咳毒素敏感的G蛋白（Gi）偶联。 还公开了编码受体的核酸和相关筛选和治疗方法。
-
公开(公告)号：US06680373B2
公开(公告)日：2004-01-20
申请号：US09947922
申请日：2001-09-07
IPC分类号： C12Q168
CPC分类号： G01N33/5091 , A61K38/00 , A61K48/00 , C07K14/705 , G01N33/5008 , G01N33/502 , G01N33/5041 , G01N33/5044 , G01N33/5094 , G01N33/566 , G01N2500/10
摘要： A novel subtype of the P2-purinergic receptor, referred to as the P2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor, antibodies that bind to the receptor and associated screening and therapeutic methods also are disclosed.
摘要翻译： 公开了称为P2U2受体的P2-嘌呤能受体的新亚型。 该受体由其四种激动剂按以下特异性顺序激活：UTP> UDP> ADP> ATP。 还公开了编码受体的核酸，与受体结合的抗体以及相关的筛选和治疗方法。
-
公开(公告)号：US5871963A
公开(公告)日：1999-02-16
申请号：US559524
申请日：1995-11-15
CPC分类号： G01N33/5091 , C07K14/705 , G01N33/5008 , G01N33/502 , G01N33/5044 , A61K38/00 , A61K48/00 , G01N2500/10
摘要： A novel subtype of the P.sub.2 -purinergic receptor, referred to as the P.sub.2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor and associated screening and therapeutic methods also are disclosed.
摘要翻译： 公开了称为P2U2受体的P2-嘌呤能受体的新亚型。 该受体由其四种激动剂按以下特异性顺序激活：UTP> UDP> ADP> ATP。 还公开了编码受体的核酸和相关筛选和治疗方法。
-
公开(公告)号：US20110212983A1
公开(公告)日：2011-09-01
申请号：US12642379
申请日：2009-12-18
申请人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles Marlowe
发明人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles Marlowe
IPC分类号： A61K31/506 , C07D409/12 , C07D417/12 , A61K31/427 , A61K31/4436 , A61P9/10 , A61P9/00 , A61P9/04
CPC分类号： C07D239/22 , C07D239/48 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D495/04
摘要： Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.
摘要翻译： 式（I）至（VI）的新型化合物，其更具体地包括作为有效的血小板ADP受体抑制剂的磺酰脲衍生物，磺酰基硫脲衍生物，磺酰基胍衍生物，磺酰基氰胍基衍生物，硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物。 这些衍生物可用于各种药物组合物中，并且对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括施用治疗有效量的式（I） - （VI）化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：US20100234350A1
公开(公告)日：2010-09-16
申请号：US12559389
申请日：2009-09-14
申请人： Robert M. Scarborough , Wolin Huang , Charles K. Marlowe , Kim A. Kane-McGuire , Hans-Michael Jantzen , David M. Sedlock
发明人： Robert M. Scarborough , Wolin Huang , Charles K. Marlowe , Kim A. Kane-McGuire , Hans-Michael Jantzen , David M. Sedlock
IPC分类号： A61K31/55 , C07D209/44 , A61K31/4035 , C07D401/04 , A61K31/4439 , C07D239/02 , A61K31/505 , C07D277/20 , A61K31/426 , C07D243/24 , A61K31/5513 , C07D223/14 , C07D239/72 , A61K31/517 , C07D215/00 , A61K31/47 , C07D413/14 , A61K31/5377 , C07D471/02 , A61K31/437 , C07D513/02 , C07D285/18 , A61K31/542 , C07D237/26 , A61K31/502 , C07D333/34 , A61K31/381 , A61P9/00 , A61P9/10 , A61P7/02
CPC分类号： C07D487/04 , C07D209/48 , C07D239/22 , C07D239/48 , C07D239/50 , C07D239/96 , C07D333/34 , C07D333/62 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D521/00
摘要： Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
摘要翻译： 式（I）至（VIII）的新型化合物，其更具体地包括作为有效的血小板ADP受体抑制剂的磺酰脲衍生物，磺酰基硫脲衍生物，磺酰基胍衍生物，磺酰氰基胍衍生物，硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物。 这些衍生物可用于各种药物组合物中，并且对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括施用治疗有效量的式（I）至（VIII）化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：US20120149688A1
公开(公告)日：2012-06-14
申请号：US13270193
申请日：2011-10-10
申请人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-Maguire
发明人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-Maguire
IPC分类号： A61K31/55 , C07D471/04 , C07D487/04 , A61K31/4725 , A61K31/517 , A61P9/10 , A61K31/519 , A61K31/4709 , A61K31/404 , A61K31/5513 , A61P7/02 , A61P9/00 , C07D409/12 , A61K31/4745
CPC分类号： C07D487/04 , C07D209/48 , C07D239/22 , C07D239/48 , C07D239/50 , C07D239/96 , C07D333/34 , C07D333/62 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D521/00
摘要： Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
摘要翻译： 式（I）和（VIII）的新型化合物，其更具体地包括作为有效血小板ADP受体抑制剂的磺酰脲衍生物，磺酰基硫脲衍生物，磺酰基胍衍生物，磺酰基氰胍基衍生物，硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物。 这些衍生物可用于各种药物组合物中，并且对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括施用治疗有效量的式（I）至（VIII）化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：US08524721B2
公开(公告)日：2013-09-03
申请号：US13270193
申请日：2011-10-10
申请人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-Maguire
发明人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-Maguire
IPC分类号： C07D521/00 , C07D409/12 , C07D209/48 , A61K31/4035 , A61P7/02
CPC分类号： C07D487/04 , C07D209/48 , C07D239/22 , C07D239/48 , C07D239/50 , C07D239/96 , C07D333/34 , C07D333/62 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D521/00
摘要： Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
摘要翻译： 式（I）和（VIII）的新型化合物，其更具体地包括作为有效血小板ADP受体抑制剂的磺酰脲衍生物，磺酰基硫脲衍生物，磺酰基胍衍生物，磺酰基氰胍基衍生物，硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物。 这些衍生物可用于各种药物组合物中，并且对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括施用治疗有效量的式（I）至（VIII）化合物或其药学上可接受的盐的步骤。
-
公开(公告)号：US08067428B2
公开(公告)日：2011-11-29
申请号：US12559389
申请日：2009-09-14
申请人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-McGuire
发明人： Robert M. Scarborough , Hans-Michael Jantzen , Wolin Huang , David M. Sedlock , Charles K. Marlowe , Kim A. Kane-McGuire
IPC分类号： C07D521/00 , C07D409/12 , C07D209/48 , A61K31/4035 , A61P7/02
CPC分类号： C07D487/04 , C07D209/48 , C07D239/22 , C07D239/48 , C07D239/50 , C07D239/96 , C07D333/34 , C07D333/62 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D521/00
摘要： Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.
摘要翻译： 式（I）至（VIII）的新型化合物，其更具体地包括作为有效的血小板ADP受体抑制剂的磺酰脲衍生物，磺酰基硫脲衍生物，磺酰基胍衍生物，磺酰氰基胍衍生物，硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物。 这些衍生物可用于各种药物组合物中，并且对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括施用治疗有效量的式（I）至（VIII）化合物或其药学上可接受的盐的步骤。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.056 秒)
